ANNX (Annexon) 3-Year ROIIC % : 1,081.98% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Annexon 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Annexon's 3-Year ROIIC % for the quarter that ended in Dec. 2024 was 1,081.98%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Annexon's 3-Year ROIIC % or its related term are showing as below:

ANNX's 3-Year ROIIC % is ranked better than
95.38% of 1385 companies
in the Biotechnology industry
Industry Median: -14.57 vs ANNX: 1081.98

Annexon 3-Year ROIIC % Historical Data

The historical data trend for Annexon's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annexon 3-Year ROIIC % Chart

Annexon Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

3-Year ROIIC %

Get a 7-Day Free Trial

-274.05

-297.50

-217.74

1,081.98

Annexon Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
3-Year ROIIC %	Get a 7-Day Free Trial															-217.74	-	-	-	1,081.98

Competitive Comparison of Annexon's 3-Year ROIIC %

For the Biotechnology subindustry, Annexon's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annexon's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexon's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Annexon's 3-Year ROIIC % falls into.

Save Embed

;

Save Embed

;

Annexon 3-Year ROIIC % Calculation

Annexon's 3-Year ROIIC % for the quarter that ended in Dec. 2024 is calculated as:

3-Year ROIIC %	=	3-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	3-Year Incremental Invested Capital^**
	=	( -154.073 (Dec. 2024) - -130.713 (Dec. 2021) )	/	( 42.102 (Dec. 2024) - 44.261 (Dec. 2021) )
	=	-23.36	/	-2.159
	=	1,081.98%^***

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Annexon (NAS:ANNX) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Annexon 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Annexon's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Annexon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexon Inc (NAS:ANNX) » Definitions » 3-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005

Website

https://www.annexonbio.com

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Executives

Dean Richard Artis	officer: EVP & Chief Scientific Officer	C/O ANNEXON, INC., 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR, BRISBANE CA 94005
Jennifer Lew	officer: EVP & Chief Financial Officer	2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Ted Yednock	officer: EVP & Chief Innovation Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg	officer: Chief Medical Officer	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Overdorf	officer: EVP & Chief Business Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Douglas Love	director, officer: President & CEO	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William H. Carson	director	C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK NY 10016
Muneer A Satter	director	C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Bain Capital Life Sciences Fund, L.p.	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bettina M. Cockroft	director	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Larry Mattheakis	officer: Chief Scientific Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Sanjay Keswani	officer: EVP & Chief Medical Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Clarus Lifesciences Iii, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017